The present study aimed to examine the chemosensitivity of CD34+/− AML subclones during the first days of therapy, based on the expression of CD34, known to be the main marker distinguishing maturation stages of leukemic cells, and to explore differences in the ability of these subclones to escape apoptosis. Here, CD34 is linked to acute myeloid leukemia.